← Back to Search

SGLT-2 Inhibitor

Empagliflozin for Heart Attack

Phase 3
Waitlist Available
Research Sponsored by Boehringer Ingelheim
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 26 months
Awards & highlights

Study Summary

This trial is testing whether a medicine called empagliflozin helps to lower the chances of having to go to the hospital for heart failure and whether it lowers the chances of dying from cardiovascular disease.

Eligible Conditions
  • Heart Attack

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 26 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 26 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Composite of time to first heart failure hospitalisation or all-cause mortality
Secondary outcome measures
Time to CV mortality
Total number of HHF or all-cause mortality
Total number of hospitalisations for MI or all-cause mortality
+2 more

Side effects data

From 2021 Phase 3 trial • 5988 Patients • NCT03057951
15%
Cardiac failure
7%
Hypertension
7%
Urinary tract infection
7%
Hypotension
6%
Hyperkalaemia
6%
Fall
6%
Renal impairment
5%
Atrial fibrillation
5%
Diabetes mellitus
4%
Anaemia
4%
Hyperuricaemia
3%
Acute kidney injury
3%
Pneumonia
2%
Acute myocardial infarction
2%
COVID-19
2%
Cardiac failure congestive
2%
Death
1%
Cardiac failure chronic
1%
Myocardial infarction
1%
Angina pectoris
1%
Angina unstable
1%
Ventricular tachycardia
1%
COVID-19 pneumonia
1%
Cellulitis
1%
Sepsis
1%
Chronic kidney disease
1%
Coronary artery disease
1%
Chronic obstructive pulmonary disease
1%
Basal cell carcinoma
1%
Cerebrovascular accident
1%
Ischaemic stroke
1%
Syncope
1%
Transient ischaemic attack
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
10 mg Empagliflozin

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: EmpagliflozinExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Empagliflozin
2017
Completed Phase 4
~181750

Find a Location

Who is running the clinical trial?

Boehringer IngelheimLead Sponsor
2,499 Previous Clinical Trials
11,333,244 Total Patients Enrolled
Eli Lilly and CompanyIndustry Sponsor
2,610 Previous Clinical Trials
3,193,905 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is patient recruitment still open for this research project?

"From what is available on clinicaltrials.gov, it appears as though this trial is still recruiting patients. The trial was initially posted on December 16th, 2020 and was updated on November 1st, 2020."

Answered by AI

How many people will be participating in this experiment?

"In order to carry out this research, 6500 individuals that meet the eligibility criteria are required. The sponsor, Eli Lilly and Company, will manage the trial from various locations, such as Cardiology Associates Research, LLC in Tupelo, Mississippi and University Hospital (LHSC) in London, Ontario."

Answered by AI

Do you know of any other research centers conducting this same trial in Canada?

"Currently, this trial is operational in 100 distinct locations, which can be found in Tupelo, London, Toronto and 100 other cities. If you are considering participating in this trial, it may be beneficial to choose a location near you to avoid having to travel long distances."

Answered by AI

Are there any other Empagliflozin studies that have been completed?

"Empagliflozin is being trialed in 50 different clinical studies, 13 of which are in Phase 3. The largest concentration of these trials is in Münster, Maryland; however, there are 1008 total locations running these sorts of tests."

Answered by AI

What is Empagliflozin approved for by the FDA?

"Empagliflozin is a medication that is commonly used to cardiovascular diseases. It is also used to ameliorate conditions such as cardiovascular mortality, heart failure, and type 2 diabetes mellitus."

Answered by AI

What is the government's opinion on the safety of Empagliflozin?

"Empagliflozin has received a score of 3 out of 3 for safety by our team at Power. This is due to the fact that this is a Phase 3 trial, and thus there is data supporting both efficacy and safety."

Answered by AI

Is this a pioneering research project?

"Empagliflozin has 50 ongoing clinical trials in 237 cities and 43 countries. Boehringer Ingelheim's initial Phase 3 trial for Empagliflozin completed in 2018 with 175 patients. Since then, 18372 more trials have been completed."

Answered by AI

Who else is applying?

What state do they live in?
Texas
California
British Columbia
Other
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
What site did they apply to?
Arkansas Cardiology, PA
Comprehensive Cardiovascular Medical Group
Valley Clinical Trials, Inc.
Recent research and studies
clinicaltrials.govStudy
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
2020. "EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04509674.
~1505 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top